About ICON

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. We specialize in the strategic development, management, and analysis of programs that support Clinical Development — from compound selection to Phase I-IV clinical studies. Our services can be implemented separately or as part of a comprehensive full service clinical program to help expedite the time it takes to bring a drug to market and monitor its performance and safety post approval.

A Global Company

With 68 offices in more than 33 countries, ICON has the global resources, systems, and infrastructure in place to take on large, multi-center, multinational trials, but remains flexible enough to provide an individual, highly personalized service for locally managed projects.

Our global services are offered through the expertise of our five international divisions:

• ICON Clinical Research: phase IIb – IV Clinical trial management, biostatistics, data management, patient registries, health economics, outcomes research
• ICON Development Solutions: product development strategy/planning, early phase clinical development, regulatory affairs, pharmacokinetics/biopharmaceutics
• ICON Central Laboratories: global central laboratory services dedicated exclusively to Clinical Trials
• ICON Medical Imaging: medical imaging based product development solutions
• ICON Contracting Solutions: contract and permanent staffing solutions for top pharmaceutical and biotech companies

ICON Global Medical And Safety Services

Assessing drug safety is essential to the success of all clinical research projects. ICON understands the safety lifecycle — from project inception through commercialization. We have the global pharmacovigilance expertise and a proven track record.
Click here to access the Global Medical and Safety Services website.

Proven Experience and Success

ICON is renowned for its core competency in project management underpinned by comprehensive and consistent processes which conform to ISO 9001:2000. We work with over 350 of the world's leading pharmaceutical, biotechnology, and medical device companies. To date, ICON teams have successfully conducted over 3,000 development projects and over 2,300 consultancy engagements across all major therapeutic areas. We are fully committed to delivering projects on time, on budget, and focus on results to achieve excellence in everything we do.

ICON has been recognized as one of the world's leading Contract Research Organizations through a number of high profile industry awards:

• Leading CRO for International Project Execution
  Lehman Brothers Equity Research, R&D Managers Survey 2007
  
  
• Sponsors' Favorite CRO to work with
  Thomson CenterWatch/William Blair, Sponsor Survey 2007
  
  
• Sponsors' Favorite Full Service CRO
  Thomson CenterWatch/William Blair, Sponsor Survey 2007
  
  
• North American Pharmaceutical & Biotechnology Service Provider of the Year
  Frost & Sullivan, Best Practice Awards 2007

ICON Insight Spring 2009 Issue

ICON Insight Summer 2009 Issue

ICON Webinar

Explore The Implications of the Cardiorenal Panel Meeting on Statin Drugs
9th February, 2010
11:00 AM - 12:00 PM EST / 8:00 - 9:00 AM PT / 16:00 - 17:00 GMT

This webinar will review the implications of the recent ruling by the FDA Cardiorenal Advisory Panel on December 15, 2009 that voted in favor of approval for Rosuvastatin. The trial results, from the study, called Jupiter, showed that Rosuvastain improves CV outcomes when given for primary prevention in 18,000 asymptomatic patients. Most of these patients had normal cholesterol. The combined risk of heart attack, stroke and heart-related death fell by 47%.
Click here for more information

To Contact Our European Headquarters:

ICON Plc
South County Business Park
Leopardstown
Dublin 18
IRELAND
Phone: +353 (1) 291 2000
Fax: +353 (1) 291 2700
E-Mail: info@iconclinical.com
Contact: Susan Dempsey